doi: 10.1186/s13045-019-0720-y 12 TangBZhuJWangYChenWFangSMaoWet al
The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
However, GLUT3-targeted therapy has limitations in application, including potential neurotoxicity and restrictions imposed by the blood-brain barrier in most treatment scenarios
Board Certified Nurse Practitioner APRN NPI: 1467595330 Board Certified Physician MD NPI: 1780944918 Personalized GLP-1 programs start from $149/month ($37.25/week), plus a clinical service and support fee ($79 for new and repeat patients)
You or the patient must also fill out all the medical release forms before any treatment, otherwise, this service may be refused by the Onsite Med Spa practitioner
.png?sfvrsn=445e9145_3)
